ALNY
Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$266.11
+0.61%Forward multiples
Based on analyst estimates
- P/E forward
- 31.40x
- P/E 2026E
- 39.56x
- P/E 2027E
- 26.19x
- P/E 2028E
- 21.01x
- P/S forward
- 5.60x
Trailing multiples
Trailing twelve months
- P/E TTM
- 43.62x
- PEG TTM
- 1.12x
- Price / book
- 26.30x
- Price / sales
- 7.41x
- Price / cash flow
- 56.12x
Enterprise value
- Enterprise value
- $33.6B
- EV / sales
- 6.99x
- EV / EBITDA
- 29.18x
- EV / EBIT
- 33.57x
- Market cap
- $35.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026